U.S. markets open in 7 hours 7 minutes
  • S&P Futures

    4,540.75
    +4.25 (+0.09%)
     
  • Dow Futures

    35,566.00
    +9.00 (+0.03%)
     
  • Nasdaq Futures

    15,360.50
    +19.50 (+0.13%)
     
  • Russell 2000 Futures

    2,290.70
    +1.90 (+0.08%)
     
  • Crude Oil

    84.59
    +0.83 (+0.99%)
     
  • Gold

    1,799.70
    +3.40 (+0.19%)
     
  • Silver

    24.54
    +0.09 (+0.37%)
     
  • EUR/USD

    1.1660
    +0.0015 (+0.13%)
     
  • 10-Yr Bond

    1.6550
    0.0000 (0.00%)
     
  • Vix

    15.43
    +0.42 (+2.80%)
     
  • GBP/USD

    1.3774
    +0.0014 (+0.10%)
     
  • USD/JPY

    113.5400
    +0.0800 (+0.07%)
     
  • BTC-USD

    61,912.48
    +924.23 (+1.52%)
     
  • CMC Crypto 200

    1,453.34
    -49.70 (-3.31%)
     
  • FTSE 100

    7,204.55
    +14.25 (+0.20%)
     
  • Nikkei 225

    28,600.41
    -204.44 (-0.71%)
     

Bio-Path Holdings to Present at the 2021 American Association for Cancer Research Annual Meeting

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

HOUSTON, March 11, 2021 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced an upcoming virtual poster presentation at the 2021 American Association for Cancer Research (AACR) Annual Meeting, taking place April 10-15 and May 17-21, 2021.

Dr. Maria Gagliardi, a Research Scientist at Bio-Path Holdings, will discuss pre-clinical studies of BP1002 (liposomal Bcl-2 antisense) in combination with decitabine as a potential treatment against venetoclax-resistant cells.

Details for the virtual poster presentation are as follows:

Date: April 10, 2021
Presentation Time: 8:30 am Eastern Time
Session: Biological Therapeutic Agents
Abstract Number: 939
Title: The combination of liposomal Bcl-2 antisense oligonucleotide (BP1002) with decitabine is efficacious in venetoclax-resistant cells

About Bio-Path Holdings, Inc.

Bio-Path is a biotechnology company developing DNAbilize®, a novel technology that has yielded a pipeline of RNAi nanoparticle drugs that can be administered with a simple intravenous transfusion. Bio-Path’s lead product candidate, prexigebersen (BP1001, targeting the Grb2 protein), is in a Phase 2 study for the treatment of blood cancers and prexigebersen-A, a drug product modification of prexigebersen, is under consideration by the FDA to commence Phase 1 studies in solid tumors. This is followed by BP1002, targeting the Bcl-2 protein, where it is being evaluated in a Phase 1 study in advanced lymphoma and chronic lymphocytic leukemia patients.

For more information, please visit the Company's website at http://www.biopathholdings.com.

Contact Information:

Investors

Will O’Connor
Stern Investor Relations, Inc.
212-362-1200
will@sternir.com

Doug Morris
Investor Relations
Bio-Path Holdings, Inc.
832-742-1369